BIRCHVIEW CAPITAL LP
Q1 2022 Form 13-F

BURLINGTON, VERMONT
CIK 0001618205 · CRD 170534 · SEC-registered investment adviser
$138.9M Reported Value Total

BIRCHVIEW CAPITAL, LP reports 14 total accounts under management (AUM). There are 14 discretionary accounts valued at $231,455,662, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
13 funds · $112.3M gross asset value
Hedge Fund: $97.5M · Private Equity Fund: $14.7M
Source: Form ADV filed 2026-10-13
Reported value
$138.9M
Quarter over quarter
-9.7%
Holdings
63
Top-10 concentration
72.0%

Key People

Form ADV owners & control persons
Matthew William Strobeck
CHIEF EXECUTIVE OFFICER AND MANAGING PARTNER
Nicholas Renegar
DIRECTOR OF QUANT STRATEGIES
Benjamin Grant Small
CHIEF OPERATING OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2022 13F record

Q1 2022 13F filing summary

Q1 2022 Form 13F portfolio summary
Period of report March 31, 2022
Filed May 13, 2022
Form 13F-HR
Reported value $138.9M
Positions 63
Change in reported value -10.4%
New positions 1
Exited positions 5
Position turnover 8.8%
Top-10 concentration 72.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
79 $173.1M
Q2 2026 13F
Filed Aug 14, 2026
72 $213.8M
Q1 2026 13F
Filed May 15, 2026
73 $175.7M
Q4 2025 13F
Filed Feb 13, 2026
68 $170.8M
Q3 2025 13F
Filed Nov 13, 2025
69 $132.4M
Q2 2025 13F
Filed Aug 14, 2025
71 $100.7M
Q1 2025 13F
Filed May 15, 2025
68 $115.2M
Q4 2024 13F
Filed Feb 14, 2025
68 $122.9M
Q3 2024 13F
Filed Nov 14, 2024
61 $115.5M
Q2 2024 13F
Filed Aug 13, 2024
60 $108.2M
Q1 2024 13F
Filed May 14, 2024
59 $122.7M
Q4 2023 13F
Filed Feb 14, 2024
58 $127.8M
Q3 2023 13F
Filed Nov 14, 2023
51 $117.7M
Q2 2023 13F
Filed Aug 8, 2023
54 $133.4M
Q1 2023 13F
Filed May 12, 2023
55 $127.7M
Q4 2022 13F
Filed Feb 3, 2023
57 $141.6M
Q3 2022 13F
Filed Nov 7, 2022
60 $142.0M
Q2 2022 13F
Filed Aug 12, 2022
60 $137.5M
Q1 2022 13F
Filed May 13, 2022
63 $138.9M
Q4 2021 13F
Filed Feb 14, 2022
67 $155.1M

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2022

Largest Q1 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 BMY BRISTOL-MYERS SQUIBB CO $55.1M 39.65%
2 NBIX NEUROCRINE BIOSCIENCES INC $8.4M 6.02%
3 ELUT AZIYO BIOLOGICS INC $8.3M 5.96%
4 QDEL QUIDEL CORP $6.7M 4.83%
5 ACAD ACADIA PHARMACEUTICALS INC $4.8M 3.48%
6 FHTX FOGHORN THERAPEUTICS INC $4.5M 3.23%
7 ALBO ALBIREO PHARMA INC $3.4M 2.43%
8 AXDX ACCELERATE DIAGNOSTICS INC $3.2M 2.33%
9 UTHR UNITED THERAPEUTICS CORP $3.2M 2.32%
10 CLR CONTINENTAL RESOURCES INC $2.4M 1.7%
11 BIIB BIOGEN INC $2.1M 1.53%
12 BDSXXXXX BIODESIX INC $2.1M 1.52%
13 KPTI KARYOPHARM THERAPEUTICS INC $2.0M 1.43%
14 OVV OVINTIV INC $1.8M 1.33%
15 BHVN BIOHAVEN PHARMACEUTICAL HOLDING CO LTD $1.7M 1.2%
16 PRTA PROTHENA CORP PLC $1.5M 1.11%
17 MASI MASIMO CORP $1.4M 0.97%
18 ALKS ALKERMES PLC $1.3M 0.95%
19 HROW HARROW HEALTH INC $1.2M 0.88%
20 CORT CORCEPT THERAPEUTICS INC $1.1M 0.81%

Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings